|
1
|
- 1. Do you think that such an approach will render pediatric trials more
informative with respect to better dosing and study designs given the
difficulties in conducting pediatric clinical trials?
|
|
2
|
- 2. Given limited resources, please advice us on how to prioritize
pediatrics programs for applying model-based trial design?
|
|
3
|
- 3. Do you have any suggestions on how to improve the approach with
respect to closing our knowledge gaps in pediatric pharmacotherapy?
|
Notes
